SVF
Level B· Emerging Clinical EvidenceRandomized Controlled Trial

Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?

Mikłosz A., Nikitiuk BE., Chabowski A.

Randomized Controlled Trial on Type 2 Diabetes, Immune Modulation, published in Obes Rev (2022) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Obes Rev (2022)
Country
England
Reported sample size
—
PMID
34985174
DOI
10.1111/obr.13413

Abstract (original English)

Obesity is a critical risk factor for the development of metabolic diseases, and its prevalence is increasing worldwide. Stem cell-based therapies have become a promising tool for therapeutic intervention. Among them are adipose-derived mesenchymal stem cells (ADMSCs), secreting numerous bioactive molecules, like growth factors, cytokines, and chemokines. Their unique features, including immunosuppressive and immunomodulatory properties, make them an ideal candidates for clinical applications. Numerous experimental studies have shown that ADMSCs can improve pancreatic islet cell viability and function, ameliorate hyperglycemia, improve insulin sensitivity, restore liver function, counteract dyslipidemia, lower pro-inflammatory cytokines, and reduce oxidative stress in the animal models. These results prompted scientists to use ADMSCs clinically. However, up to date, there have been few clinical studies or ongoing trails using ADMSCs to treat metabolic disorders such as type 2 diabetes mellitus (T2DM) or liver cirrhosis. Most human studies have implemented autologous ADMSCs with minimal risk of cellular rejection. Because the functionality of ADMSCs is significantly reduced in subjects with obesity and/or metabolic syndrome, their efficacy is questioned. ADMSCs transplantation may offer a potential therapeutic approach for the treatment of metabolic complications of obesity, but

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies exist, but sample sizes, methodology, or follow-up remain limited, so conclusions are not firm.

How we grade evidence
Adipose TissueAnimalsCytokinesDiabetes Mellitus, Type 2HumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMetabolic DiseasesObesity
Systemic / IVType 2 DiabetesImmune Modulation
View on PubMedDOI

Related research